Report : Middle East & Africa Dry Eye Products Market Forecast to 2031 - Regional Analysis - by Product (Artificial Tears, Anti-Inflammatory Drugs, Punctal Plugs, Secretagogues, Oral Omega Supplements, and Others), Dosage Form (Eye Drops, Gel, Capsules and Tablets, and Others), Type (OTC and Prescription), and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
At 2.1% CAGR, Middle East & Africa Dry Eye Products Market is Projected to be Worth US$ 179.24 Million by 2031, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa dry eye products market was valued at US$ 151.86 million in 2023 and is expected to reach US$ 179.24 million by 2031, registering a CAGR of 2.1% from 2023 to 2031.Upsurge in geriatric population and rising prevalence of dry eye are among the critical factors attributed to drive the Middle East & Africa dry eye products market growth.
Dry eye disease (DED) ranks third among the most common reasons for visits to an ophthalmology clinic after refractive errors and cataracts, respectively. The prevalence of dry eye is particularly rising in developed nations. Dry eye is caused by multiple factors that result in discomfort, irritation, and visual disturbance.
Whereas regions like the Middle East and Africa also have increasing prevalence due to the chronic health conditions and environmental conditions. According to an article published in 2019 by the Department of Research, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, the incidence of dry eye is high among women. The primary cause of dry eye is the medication of glaucoma. The increasing incidence of dry eye is leading to the rise in direct cost of treatment. According to Ocular Surgery News, the annual direct cost for mild dry eye symptom treatment was US$ 678, for moderate dry eye symptom was US$ 771, and for the severe dry eye symptom was US$ 1,267. Thus, the increasing prevalence of dry eye is expected to drive the growth of dry eye products market.
On the contrary, side effects of eye drop and product recalls hamper the growth of Middle East & Africa dry eye products market.
Based on product, the Middle East & Africa dry eye products market is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, oral omega supplements, and others. The artificial tears segment held 47.9% market share in 2023, amassing US$ 72.77 million. It is projected to garner US$ 86.88 million by 2031 to register 2.3% CAGR during 2023–2031. Furthermore, the anti-inflammatory drugs segment is subcategorized into cyclosporine, corticosteroid, and others. Additionally, the punctal plugs segment is subsegmented into dissolvable and removable.
In terms of dosage form, the Middle East & Africa dry eye products market is segmented into eye drops, gel, capsules and tablets, and others. The eye drops segment held 64.9% share Middle East & Africa dry eye products market in 2023, amassing US$ 98.60 million. It is anticipated to garner US$ 117.65 million by 2031 to expand at 2.2% CAGR during 2023–2031.
By type, the Middle East & Africa dry eye products market is bifurcated into OTC and prescription. The OTC segment held 58.0% share of Middle East & Africa dry eye products market in 2023, amassing US$ 88.01 million. It is projected to garner US$ 106.50 million by 2031 to expand at 2.4% CAGR from 2023 to 2031.
Based on distribution channel, the Middle East & Africa dry eye products market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment held 46.0% share of Middle East & Africa dry eye products market in 2023, amassing US$ 69.88 million. It is predicted to garner US$ 82.13 million by 2031 to expand at 2.0% CAGR between 2023 and 2031.
Based on country, the Middle East & Africa dry eye products market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.1% share of Middle East & Africa dry eye products market in 2023. It was assessed at US$ 60.91 million in 2023 and is likely to hit US$ 70.82 million by 2031, registering a CAGR of 1.9% during 2023–2031.
Key players operating in the Middle East & Africa dry eye products market are Santen Pharmaceutical Co Ltd, Johnson & Johnson, OASIS Medical, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co Ltd, OCuSOFT Inc, Bausch Health Companies Inc, AbbVie Inc, Farmigea SpA, and Alcon AG, among others.
- In September 2023, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non- steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
- In April 2021, MY OASIS is a cyber platform that allows eye care practitioners to grow their brand as a dry eye resource, broaden the reach of their practice, and provide access to solutions that can improve the quality of life for dry eye patients in their region. Its simple and intuitive design ensures a pleasant user experience.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com